• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Vicarious Surgical Inc.

    7/2/25 4:30:49 PM ET
    $RBOT
    Industrial Specialties
    Health Care
    Get the next $RBOT alert in real time by email
    S-8 1 ea0248012-s8_vicarious.htm REGISTRATION STATEMENT

    As filed with the Securities and Exchange Commission on July 2, 2025

    Registration No. 333-       

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

    Vicarious Surgical Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware   87-2678169
    (State or other jurisdiction of   (I.R.S. Employer
    incorporation or organization)   Identification No.)

     

    78 Fourth Avenue
    Waltham, Massachusetts 02451
    (Address, including zip code, of registrant’s principal executive offices)

     

    Vicarious Surgical Inc. 2021 Equity Incentive Plan, as amended

    (Full title of the plan)

     

    Adam Sachs

    Chief Executive Officer

    Vicarious Surgical Inc.

    78 Fourth Street

    Waltham, Massachusetts 02451

    (617) 868-1700
    (Name, address and telephone number, including area code, of agent for service)

     

    With a copy to:

     

    Robert A. Petitt, Esq.

    Blank Rome LLP

    125 High Street

    Boston, MA 02110

    (617) 415-1200

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐ Accelerated filer ☐
    Non-accelerated filer ☒ Smaller reporting company ☒
        Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     

    EXPLANATORY NOTE

     

    This Registration Statement on Form S-8 (this “Registration Statement”) registers an aggregate of 311,046 additional shares of Class A common stock, par value $0.0001 per share (the “Class A common stock”), of Vicarious Surgical Inc. (the “Registrant”) for issuance under the Vicarious Surgical Inc. 2021 Equity Incentive Plan, as amended, which amendment was approved by the Registrant’s stockholders at the Registrant’s annual meeting of stockholders on June 27, 2025. This Registration Statement registers additional securities of the same class as other securities for which registration statements filed on Form S-8 (SEC File Nos. 333-261455, 333-261736, 333-265562, 333-273296 and 333-280538) of the Registrant are effective, and the information contained in such registration statements is hereby incorporated by reference pursuant to General Instruction E of Form S-8, except to the extent supplemented, amended or superseded by the information set forth herein. 

     

     

    PART ii

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    The following documents filed by the Registrant with the Commission are incorporated herein by reference:

     

      (a) The Registrant’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Commission on March 17, 2025;

     

      (c) The Registrant’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the Commission on May 12, 2025;

     

      (c) The Registrant’s Current Reports on Form 8-K as filed with the Commission on January 21, 2025, February 18, 2025, March 13, 2025, March 24, 2025, April 11, 2025, and June 30, 2025;

     

      (d) The description of the Registrant’s securities contained in the Registrant’s registration statement on Form 8-A (File No. 001-39384), filed by the Registrant with the Commission under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), on July 13, 2020, as updated by the description of the Registrant’s common stock filed as Exhibit 4.1 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Commission on March 17, 2025, including any amendments or reports filed for the purpose of updating such description.

      

    All reports and other documents filed by the Registrant after the date hereof pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items), prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be part hereof from the date of filing of such reports and documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for the purposes of this registration statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this registration statement.

     

    II-1

     

    Item 8. Exhibits.

     

    Exhibit
    Number
      Exhibit Description   Filed
    Herewith
      Incorporated by
    Reference
    herein from
    Form or Schedule
      Filing Date   SEC
    File/ Reg.
    Number
    4.1   Certificate of Incorporation of Vicarious Surgical Inc., as amended       Form 10-Q
    (Exhibit 3.1)
      8/12/2024   001-39384
                         
    4.2   Amended and Restated Bylaws of Vicarious Surgical Inc.       Form 8-K
    (Exhibit 3.2)
      9/23/2021   001-39384
                         
    4.3   Specimen Class A Common Stock Certificate.       Form S-8
    (Exhibit 4.4)
      6/27/2024   333-280538
                         
    4.4   Warrant Agreement, dated as of July 14, 2020, by and between Vicarious Surgical Inc. (formerly D8 Holdings Corp.) and Continental Stock Transfer & Trust Company       Form 8-K
    (Exhibit 4.1)
      7/17/2020   001-39384
                         
    5.1   Opinion of Blank Rome LLP   X            
                         
    23.1   Consent of Deloitte & Touche LLP, independent registered public accounting firm   X            
                         
    23.2   Consent of Blank Rome LLP (included in Exhibit 5.1)   X            
                         
    24.1   Power of Attorney (included on the signature page hereof)   X            
                         
    99.1+   Vicarious Surgical Inc. 2021 Equity Incentive Plan, as amended, and forms of agreement thereunder       Form 8-K
    (Exhibit 10.1)
      6/30/2025   001-39384
                         
    107   Filing Fee Table   X            

     

    + Denotes management contract or compensatory plan or arrangement

     

    II-2

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Waltham, Commonwealth of Massachusetts, on July 2, 2025.

     

      VICARIOUS SURGICAL INC.
       
      By: /s/ Adam Sachs
      Name: Adam Sachs
      Title: Chief Executive Officer

     

    POWER OF ATTORNEY

     

    Each person whose signature appears below constitutes and appoints each of Adam Sachs and Sarah Romano, acting alone or together with another attorney-in-fact, as his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for such person and in his or her name, place and stead, in any and all capacities, to sign any or all further amendments (including post-effective amendments) to this registration statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature   Title   Date
             
    /s/ Adam Sachs   Chief Executive Officer and Director   July 2, 2025
    Adam Sachs   (Principal Executive Officer)    
             
    /s/ Sarah Romano   Chief Financial Officer   July 2, 2025
    Sarah Romano   (Principal Financial and Accounting Officer)    
             
    /s/ Fuad Ahmad   Director   July 2, 2025
    Fuad Ahmad        
             
    /s/ Victoria Carr-Brendel   Director   July 2, 2025
    Victoria Carr-Brendel        
             
    /s/ Randy Clark   Director   July 2, 2025
    Randy Clark        
             
    /s/ Joseph Doherty   Director   July 2, 2025
    Joseph Doherty        
             
    /s/ David Ho   Director   July 2, 2025
    David Ho        
             
    /s/ Beverly Huss   Director   July 2, 2025
    Beverly Huss        
             
    /s/ Sammy Khalifa   Director   July 2, 2025
    Sammy Khalifa        
             
    /s/ Donald Tang   Director   July 2, 2025
    Donald Tang        

     

     

    II-3

     

    Get the next $RBOT alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $RBOT

    DatePrice TargetRatingAnalyst
    3/4/2022$16.00 → $7.00Overweight → Neutral
    Piper Sandler
    1/7/2022$16.00Outperform
    Credit Suisse
    12/7/2021$15.00Outperform
    Cowen & Co.
    11/5/2021$15.00Buy
    Canaccord Genuity
    10/18/2021$15.00Buy
    BTIG
    10/7/2021$16.00Overweight
    Piper Sandler
    More analyst ratings

    $RBOT
    SEC Filings

    See more
    • Vicarious Surgical Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

      8-K - Vicarious Surgical Inc. (0001812173) (Filer)

      7/11/25 4:30:31 PM ET
      $RBOT
      Industrial Specialties
      Health Care
    • SEC Form S-8 filed by Vicarious Surgical Inc.

      S-8 - Vicarious Surgical Inc. (0001812173) (Filer)

      7/2/25 4:30:49 PM ET
      $RBOT
      Industrial Specialties
      Health Care
    • Vicarious Surgical Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Vicarious Surgical Inc. (0001812173) (Filer)

      6/30/25 6:45:46 AM ET
      $RBOT
      Industrial Specialties
      Health Care

    $RBOT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO Sachs Adam David sold $2,176 worth of shares (279 units at $7.80), decreasing direct ownership by 0.55% to 50,444 units (SEC Form 4)

      4 - Vicarious Surgical Inc. (0001812173) (Issuer)

      6/24/25 6:49:29 PM ET
      $RBOT
      Industrial Specialties
      Health Care
    • Chief Technology Officer Khalifa Sammy sold $1,743 worth of shares (223 units at $7.81), decreasing direct ownership by 0.63% to 35,407 units (SEC Form 4)

      4 - Vicarious Surgical Inc. (0001812173) (Issuer)

      6/24/25 6:48:54 PM ET
      $RBOT
      Industrial Specialties
      Health Care
    • Chief Technology Officer Khalifa Sammy sold $1,733 worth of shares (239 units at $7.25), decreasing direct ownership by 0.67% to 35,630 units (SEC Form 4)

      4 - Vicarious Surgical Inc. (0001812173) (Issuer)

      6/4/25 2:16:21 PM ET
      $RBOT
      Industrial Specialties
      Health Care

    $RBOT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Vicarious Surgical Announces Election of New Directors

      Vicarious Surgical Inc. (NYSE:RBOT, RBOT WS)) (the "Company"), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced the election of Fuad Ahmad and Joseph Doherty to the Vicarious Surgical Board of Directors at the Company's 2025 Annual Meeting of Stockholders held on June 27, 2025. The Company also announced the departure of Ric Fulop from the Vicarious Surgical Board of Directors effective as of the Annual Meeting. "On behalf of the board, I am thrilled to welcome Fuad and Joseph to the Vicarious team. Their decades of experience and insight will be instrumental as we continue our advance towards our clinical trial and th

      6/30/25 6:45:00 AM ET
      $GSAT
      $IRIX
      $JNJ
      $MITK
      Telecommunications Equipment
      Consumer Discretionary
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Glucotrack Strengthens Board of Directors with Election of Victoria E. Carr-Brendel, PhD

      RUTHERFORD, N.J., May 28, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced today that Victoria E. Carr-Brendel, PhD, was elected to the Company's Board of Directors, effective May 22, 2025. "We are delighted to welcome Dr. Carr-Brendel to Glucotrack's Board of Directors," said Paul V. Goode, PhD, President and Chief Executive Officer of Glucotrack. "With her exceptional leadership in medical devices and deep expertise in implantable technologies, she will be an invaluable addition to the Board as we advance our continuous blood glucose monito

      5/28/25 8:30:00 AM ET
      $GCTK
      $RBOT
      Medical/Dental Instruments
      Health Care
      Industrial Specialties
    • Vicarious Surgical Reports First Quarter 2025 Financial Results

      Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company") (NYSE:RBOT, RBOT WS)), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced financial results for the first quarter ended March 31, 2025. Management will host a corresponding conference call at 4:30 p.m. ET today, May 12, 2025. "Following years of meticulous work to develop and advance our surgical system and proprietary decoupled actuating technology, we are just a few quarters away from our biggest milestone yet - our first clinical patients. 2025 will be the year Vicarious Surgical evolves into a clinical-stage company and demonstrates the immense value of o

      5/12/25 4:05:00 PM ET
      $RBOT
      Industrial Specialties
      Health Care

    $RBOT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Vicarious Surgical downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Vicarious Surgical from Overweight to Neutral and set a new price target of $7.00 from $16.00 previously

      3/4/22 4:51:18 AM ET
      $RBOT
      Industrial Specialties
      Health Care
    • Credit Suisse initiated coverage on Vicarious Surgical with a new price target

      Credit Suisse initiated coverage of Vicarious Surgical with a rating of Outperform and set a new price target of $16.00

      1/7/22 7:09:02 AM ET
      $RBOT
      Industrial Specialties
      Health Care
    • Cowen & Co. initiated coverage on Vicarious Surgical with a new price target

      Cowen & Co. initiated coverage of Vicarious Surgical with a rating of Outperform and set a new price target of $15.00

      12/7/21 7:31:51 AM ET
      $RBOT
      Industrial Specialties
      Health Care

    $RBOT
    Leadership Updates

    Live Leadership Updates

    See more
    • Vicarious Surgical Announces Appointment of Sarah Romano as Chief Financial Officer

      Ms. Romano brings decades of experience with a strong track record in financial strategy and corporate development Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company") (NYSE:RBOT, RBOT WS)), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced the appointment of Sarah Romano as Chief Financial Officer (CFO), effective April 1, 2025. Ms. Romano will oversee Vicarious Surgical's financial strategy, leveraging decades of financial leadership experience in capital markets. With exceptional strategic acumen, Ms. Romano has a proven record of driving growth and value creation in public companies, particularly in the h

      3/13/25 8:30:00 AM ET
      $RBOT
      Industrial Specialties
      Health Care
    • Vicarious Surgical Strengthens Executive Team with Appointment of Randy Clark as Company President

      Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company") (NYSE:RBOT, RBOT WS))), a next-generation robotics technology company seeking to improve patient outcomes as well as both the cost and efficiency of surgical procedures, today announced that Randy Clark has been appointed President effective today, January 29, 2024. As Vicarious Surgical prepares for its next phase of growth following the anticipated finalization of the Vicarious Surgical Version 1.0 System ("V1.0"), the newly established role of President is designed to fortify organizational alignment and focus on the Company's long-term needs and objectives. Reporting to Chief Executive Officer Adam Sachs, Mr. Clark will a

      1/29/24 8:30:00 AM ET
      $RBOT
      Industrial Specialties
      Health Care
    • Vicarious Surgical Announces Changes to Board of Directors

      Victoria Carr-Brendel, Ph.D. Elected to Board of Directors Tech-Focused Venture Capitalist Phil Liang to Resign Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company"), a next-generation robotics company seeking to improve the cost, efficiency, and outcomes of surgical procedures, today announced the appointment of Victoria Carr-Brendel, Ph.D. to the Vicarious Surgical Board of Directors effective today, January 23, 2023. The Company also announced the resignation of technology-focused venture capitalist Phil Liang from the Vicarious Surgical Board of Directors effective as of today. "On behalf of the board, I'd like to thank Phil for his critical guidance and expertise as Vicari

      1/23/23 4:10:00 PM ET
      $RBOT
      Industrial Specialties
      Health Care

    $RBOT
    Financials

    Live finance-specific insights

    See more
    • Vicarious Surgical Reports First Quarter 2025 Financial Results

      Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company") (NYSE:RBOT, RBOT WS)), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced financial results for the first quarter ended March 31, 2025. Management will host a corresponding conference call at 4:30 p.m. ET today, May 12, 2025. "Following years of meticulous work to develop and advance our surgical system and proprietary decoupled actuating technology, we are just a few quarters away from our biggest milestone yet - our first clinical patients. 2025 will be the year Vicarious Surgical evolves into a clinical-stage company and demonstrates the immense value of o

      5/12/25 4:05:00 PM ET
      $RBOT
      Industrial Specialties
      Health Care
    • Vicarious Surgical to Report First Quarter 2025 Financial Results on May 12, 2025

      Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company") (NYSE:RBOT, RBOT WS)), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced it will report financial results for the first quarter ended March 31, 2025 after the market closes on Monday, May 12, 2025. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by dialing +1 833-470-1428 for domestic callers or +1 404-975-4839 for international callers, using access code: 316641. A live and archived webcast of the event will be available at https://investor.v

      4/28/25 4:05:00 PM ET
      $RBOT
      Industrial Specialties
      Health Care
    • Vicarious Surgical Reports Fourth Quarter and Full Year 2024 Financial Results

      Version 1.0 System Integration Complete; Progressing Towards First Clinical Use Achieved 2024 Cash Burn Guidance; Sets 2025 Cash Burn Guidance of $50 Million Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company") (NYSE:RBOT, RBOT WS)), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced financial results for the quarter and full year ended December 31, 2024. Management will host a corresponding conference call at 4:30 p.m. ET today, March 17, 2025. "2024 was a pivotal year of progress for Vicarious Surgical, as we expanded our strategic hospital partnerships with LSU Health New Orleans, Temple Health, and Univers

      3/17/25 4:05:00 PM ET
      $RBOT
      Industrial Specialties
      Health Care

    $RBOT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Vicarious Surgical Inc. (Amendment)

      SC 13G/A - Vicarious Surgical Inc. (0001812173) (Subject)

      2/13/24 4:36:42 PM ET
      $RBOT
      Industrial Specialties
      Health Care
    • SEC Form SC 13G/A filed by Vicarious Surgical Inc. (Amendment)

      SC 13G/A - Vicarious Surgical Inc. (0001812173) (Subject)

      8/15/23 10:28:36 AM ET
      $RBOT
      Industrial Specialties
      Health Care
    • SEC Form SC 13D/A filed by Vicarious Surgical Inc. (Amendment)

      SC 13D/A - Vicarious Surgical Inc. (0001812173) (Subject)

      8/9/23 5:10:57 PM ET
      $RBOT
      Industrial Specialties
      Health Care